In summary, HG is a crucial risk factor for the progression of HPMC injury, and anti-LOX-1 via an AT2 agonist may reverse pathological damage and may be a new thought for the clinical treatment of PF. This evidence concerns the gene OLR1 and pemphigus foliaceus.